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Abstract
Introduction
Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the preferred first-
line treatment of advanced adenocarcinoma of the lung that harbors EGFR activating tyro-
sine kinase domain mutations. Most data available pertain to Asian populations in which
such mutations are more prevalent. We report on the long-term results of first-line treatment
with erlotinib in Caucasian patients with advanced adenocarcinoma of the lung that have a
somatic EGFR mutation in their tumor.
Methods
Multicenter academic prospective phase II study with erlotinib in patients with an activating
EGFR tyrosine kinase (TK) domain somatic mutation (any exon encoding the kinase
domain) in the tumor and no prior treatment for their advanced disease.
Results
Phenotypic preselecting of 229 patients led to a high EGFR mutation detection rate of 24%
of which 46 patients were included in the phase II study. With a progression free survival
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(PFS) of 81% at three months the study met its primary endpoint for presumed superiority
over chemotherapy. With an overall median PFS of 11 months and a median overall sur-
vival (OS) of 23 months, the results compare favorably with results obtained in randomized
studies using TKI in first line in EGFRmutation positive adenocarcinoma of the lung.
Conclusion
The present study reinforces the use of EGFR tyrosine kinase inhibition (TKI) as a first line
treatment of choice for advanced adenocarcinoma of the lung carrying an activating EGFR
mutation. The mutation rate in preselected Caucasian patients is higher than previously
reported. Issues relevant for clinical practice are discussed.
Trial Registration
ClinicalTrials.gov NCT00339586
Introduction
Patients with advanced non-small cell lung cancer (NSCLC) are incurable with a low probabil-
ity for long-term survival. With platinum-based doublet chemotherapy a response rate of
around 25% and a median OS of about 10–12 months can be obtained in metastatic disease [1]
corresponding to a PFS of 60% or less at 3 months [2]
A novel approach to the treatment of advanced NSCLC was introduced with the use of
agents blocking the tyrosine kinase part of the Epidermal Growth Factor Receptor (EGFR).
Some patients had dramatic responses to these EGFR tyrosine kinase inhibitors (TKI’s) [3, 4].
Ten years ago it became clear that mutations in the exons coding for the intracellular EGFR
kinase domain, in particular in exon 19 and 21 highly increase the sensitivity to EGFR TKI’s [5,
6]. These mutations have been observed in 10% or less of all lung cancers tested, in 30% of ade-
nocarcinoma of the lung if the smoking history was maximally 15 years and up to 50% in
never-smokers [7], although these figures depend highly on the ethnicity of the population
tested, being much higher in East-Asian populations than in Caucasians.
Most (90%) sensitizing mutations are found in exon 19 and 21. Mutations in exon 20 are
generally not associated with increased sensitivity towards reversible TKI’s [8]. The overall
response rate (ORR) to TKI in EGFR mutant lung cancers varies between 60 and 90% [9].
Gefitinib in an Asian population [10, 11], and erlotinib, in both a Caucasian [12] and an
Asian [13] population, were validated as superior to chemotherapy in terms of PFS in patients
whose tumors harbor sensitizing driver mutations in the EGFR gene and are therefore recom-
mended as the preferred first-line therapies for these patients.
FIELT (First line Inhibitor of EGFR in Lung cancer Treatment) is a prospective academic
study investigating the efficacy and tolerability of first-line treatment with erlotinib in newly
diagnosed advanced adenocarcinoma of the lung carrying EGFR kinase domain mutations, as
well as the feasibility of inserting genomic testing in a multicenter clinical setting (S1 Text).
The study aimed to estimate whether first-line erlotinib could reach an efficacy threshold
higher than chemotherapy.
At the time of initiation of FIELT in 2006, advanced lung cancer was treated indiscrimi-
nately with platinum-based chemotherapy and no data were available on the prospective first-
line use of any EGFR TKI in phenotypically or genotypically selected NSCLC, while only retro-
spective data were available for gefitinib [14].
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Materials and Methods
The study was an academic study registered at clinicaltrials.gov as NCT00339586 (S1 Text).
Patient eligibility
Key eligibility criteria were locally advanced or metastatic (Stage IIIB or Stage IV) adenocarci-
noma of the lung. Radiotherapy and adjuvant or neo-adjuvant chemotherapy completed more
than six months before inclusion were allowed. Patients should not have received previous che-
motherapy for metastatic disease and had to have a smoking history of less than 15 years and
have stopped smoking more than one year before diagnosis.
Measurable disease was not mandatory. An ECOG performance status of 0–3 was required.
Previously diagnosed and treated central nervous system metastases or spinal cord compres-
sion with evidence of stable disease for at least two months was permitted. Specific exclusion
criteria were: pre-existing symptomatic interstitial lung disease, not related to the current
malignancy, and gastrointestinal disease or concomitant food or drug intake which could
impair absorption and metabolism of erlotinib. Significant ophthalmological abnormalities,
especially severe dry eye syndrome, keratoconjunctivitis sicca, Sjögren syndrome, severe expo-
sure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions were
also exclusion criteria.
Standard phase II selection criteria were applicable for organ function. Separate signed
informed consents were required for mutation testing and subsequent inclusion in the erlotinib
treatment phase.
Study design and treatment
The study was a multicenter academic single arm phase II study in 17 university and non-uni-
versity centers in Belgium and Luxemburg (NCT00339586).
The study was approved by the institutional medical ethics review board of each participat-
ing center. The study was approved by the ethics committee of the Academisch Ziekenhuis-
Vrije Universiteit Brussel which was the leading ethics committee that according to Belgian law
approved the study in a single opinion form. Academisch Ziekenhuis-Vrije Universiteit Brussel
is the former name of the current UZ Brussel of the Vrije Universiteit Brussel (S2 Text). Partic-
ipants provided a written informed consent.
Mutation analysis
Patients had a central tumor EGFR mutation testing in the Laboratory of Medical and Molecu-
lar Oncology (LMMO) of the Oncologisch Centrum, UZ Brussel. Mutation analysis was per-
formed on DNA extracted from three consecutive 10μm thick sections of formalin fixed and
paraffin embedded material. Tissue sections were verified for the presence of a sufficient pro-
portion of malignant cells and manually macro-dissected when necessary. The collected DNA
was used to perform a hemi-nested PCR followed by a denaturing gradient gel electrophoresis
(DGGE). The PCR/DGGE method requires only very small amounts of template DNA and is
able to detect any mutation found in exon 18–21, but could not reliably detect mutations in
samples in which the tumor DNA represented less than 25% of the total DNA. Mutations were
confirmed by Sanger sequencing, but to minimize waiting time for physicians, patients could
be entered in the treatment phase of the trial, based on the DGGE results. No results had to be
revoked based on the subsequent Sanger sequence. Results were delivered to the participating
clinicians within two weeks except for cases in which the material was insufficient to obtain a
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reliable result in a first round. If a second analysis was needed for such inconclusive results, the
responsible physician was informed of the delay.
Treatment phase
Upon ascertainment of an EGFR mutation in the tumor sample, consenting patients started
erlotinib treatment 150 mg daily plus best supportive care within one week. Any mutation
found in exon 18–21 made the patient eligible for inclusion in the treatment phase of the study.
Treatment was until disease progression (RECIST definition, both for patients with or without
measurable lesions) or prohibitive toxicity. Response assessments (CT imaging and physical)
and ancillary parameters were scheduled at 6, 12, 18 and 24 weeks after treatment initiation,
thereafter every 12 weeks.
Toxicity was scored every four weeks during treatment according to the common toxicity
criteria adverse events version 3.0 [15].
The primary endpoint of the study was to establish a significant clinical benefit by achieving
at least a 70% PFS rate at three months on erlotinib. Secondary objectives and endpoints were
ORR according to RECIST criteria, response duration under erlotinib treatment, the effect on
Quality of Life (QOL), ECOG performance score, weight, the PFS and OS. The QOL results
will be reported elsewhere. The analysis of the primary efficacy endpoint was based on all sub-
jects who received at least one dose of study treatment. Data analysis cut-off was done in May
2013. If scheduled follow-up evaluations were missing, patients were considered progressive,
unless a later examination confirmed persistent remission.
The premises for the sample size determination were as follows. With platinum based che-
motherapy, a PFS of 60% or less is obtained at 3 months follow-up in advanced NSCLC [1, 16].
Taking into account the known general better tolerability of erlotinib it was proposed that if a
PFS of more than 70% could be obtained at three months, then this treatment deserved further
evaluation in the first-line treatment of advanced NSCLC. If the study would result in a PFS
less than 50% at three months, single agent erlotinib should not be further evaluated in this set-
ting as outcomes inferior in terms of efficacy to the current standard were not acceptable.
Statistical considerations
Based on these premises, a one-step Fleming design required at least 33 patients to be included
in the study (α = 10%; β = 10%). With the provision of a margin for eligibility/evaluation issues,
a prospective number to be included was set at 40 patients.
PFS and OS were estimated from the date of registration until respectively the documentation
of progression and the date of death, irrespective of the cause of death. Patients who had not pro-
gressed or died at the time of the analysis were censored at the date of last contact. PFS and OS
were calculated according to the Kaplan-Meier method with SPSS statistical software (version
20.0; SPSS Inc., Chicago, IL). Results are presented with 95% confidence intervals (CIs).
Results
Mutation analysis
From January 2006 through March 2010, tumor tissue from 229 phenotypically selected
patients was analyzed for the presence of EGFR kinase domain mutations. Tissue area ranged
from 1 mm2 to 600 mm2, with 40% of the sections smaller than 5 mm2 (mostly needle
biopsies).
Baseline material was insufficient for analysis in 24/229 samples (10%) due to the lack of
adequate material (almost no tissue material available, no tumor cells in tissue, no amplifiable
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DNA). An EGFR kinase domain mutation was found in 56 out of 205 evaluable patients (27%
or 24% of the original phenotypically selected population) (Table 1). Five mutations were pre-
viously unreported (two in exon 19, three in exon 20). The samples in which the tumor DNA
was less than 25% of the total DNA represented 30% of all samples. Although we stated to the
referring clinical investigators that a negative result should be considered as unreliable in these
cases, we did find mutations in 23% of these cases, a similar proportion as in the overall popu-
lation. A subsequent analysis with a more sensitive PNA (Peptide Nucleic Acid) PCR method
[17] showed four more mutations (7% of all mutations). The overall sensitivity of the mutation
detection method used in this study was thus 93% in evaluable samples or 90% in all samples,
also considering the pathology limitations (absence of analyzable material). Other mutations
found were: KRAS in 16%, BRAF in 2%, HER2 in 2%, HER3 in 0.4%, all mutually exclusive.
The FIELT study flow is detailed in Fig 1.
Ten patients (18%) in whom an EGFRmutation was found did not enter the phase II part of
the study because of various reasons: three became ineligible between an inconclusive first mutation
screen and identification of the EGFRmutation in a second sample, three patients died before
inclusion, one deteriorated and became ineligible and in three patients the reasons are unknown.
Patient characteristics
The characteristics of the 46 patients included in the phase II study are provided in Table 2.
Eighty five percent of patients were female. The median age was 72 yrs. (35–83 yrs.) and 37%
of the patients were aged 75 or older. Two patients were included although not strictly fulfilling
the selection criteria: one patient had a 25 pack-year of cigarette smoking history, but had since
stopped smoking for 30 years and received therefore a waiver and one patient was stage IB
(T2N0M0) recurrent disease after prior curative intent radiotherapy and was not any longer
Table 1. Mutations found.
Exon Mutations Times found (in COSMIC) DXS/COBAS*
Nucleotide/s Change Amino acid/s Change
18 c.2156G>C p.Gly719Ala 1 (31x) yes/yes
19 c.2235_2249del p.Glu746_Ala750del 22 (785x) yes/yes
c.2236_2250del p.Glu746_Ala750del 3 (360x) yes/yes
c.2237_2257delinsTCT p.Glu746_Pro753delinsValSer 1 (2x) no/yes
c.2237_2253delinsTTCCT p.Glu746_Thr751delinsValPr 1 (2x) no/no
c.2239_2248delinsC p.Leu747_A750del insPro 1 (77x) yes/yes
c.2240_2254del p.Leu747_Thr751del 1 (51x) yes/yes
c.2240_2257del p.Leu747_Pro753delins Ser 2 (121x) yes/yes
c.2248_2276delinsCCAAC p.Ala750_Ile759delinsProThr 1 (0x) no/no
c.2249_2277delinsGAAGT p.Ala750_Ile759del insGlySer 1 (0x) no/no
c.2253_2276del p.Ser752_Ile759del 1 (5x) no/no
20 c.2303_2311dup9 p.Ser768_Asp770dup 1 (1x)? no/no
c.2319_2320insAACCAC p.Pro772_His773insHisAsn 1 (0x) no/no
c.2311delAinsGTCC p.Asn771del insValHis 1 (0x) no/no
c.2311_2312insCCA p.Asp770_Asn771insThr 1 (0x) no/no
c.2310_2311insGGT p.Asp770_Asn771insGly 1 (x5) yes/yes
21 c.2573T>G p.Leu858Arg 15 (1607x) yes/yes
*indicates whether mutation is listed as detectable by Dxs Therascreen or COBAS.? = mutation that supposedly has been misnamed in the COSMIC
database
doi:10.1371/journal.pone.0147599.t001
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eligible for local curative intent treatment. Thirty eight were never smokers, seven were past
smokers and one was a current smoker.
Efficacy
The efficacy results are reported on intent to treat basis including the two ineligible patients. A
separate analysis with these two patients removed did not alter the results.
Fig 1. FIELT study flow.
doi:10.1371/journal.pone.0147599.g001
Table 2. Characteristics of the 46 patients included in the phase II study and treated with erlotinib.
Age 72 median (35–83 yrs.)
Performance status PSO = 11
PS1 = 28
PS2 = 6
PS3 = 1
Stage Stage IB = 1
Stage IIIB = 4
Stage IV = 41
Sex 7 male;39 female
EGFR Mutation Exon 19 = 27
Exon 21 = 15
Exon 20 = 3
Exon 18 = 1
Cigarette smoking history (pack years) Median 0 yrs. (0–25 yrs.)
doi:10.1371/journal.pone.0147599.t002
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The PFS rate (PFSR) at three months was 81% and at six months 72%. The median PFS was
11 months (95% CI = 9.7–12.3 months) (Fig 2).
Twenty six patients achieved a partial remission (PR) (57%), one a complete remission (CR)
(2%); ten a stable disease (SD) (22%) and nine had progressive disease (PD) as best response
(20%). Although this was not the primary endpoint, responses were confirmed by a second
measurement at least four weeks later. The clinical benefit rate (CR+PR+SD) was thus 81%.
The distribution of responses was similar in exon 19 and 21 mutations.
Median duration of response was 9.7 months (2.7–29 + months) (+ means patient alive
beyond); 9.7 months for cases with objective remissions (2.7–29+ months) and 10.3 months
for those with stable disease (4.1–23.5 months).
With a median follow-up from treatment initiation of 45 months (36–84 months), median OS
was 23 months (95% CI = 21.3–28.6+ months) (Fig 2). For patients achieving an objective response
(PR or CR), median OS was 23.9 months (3.9–52.5 months), for patients that with SD as best
response 14.5 months (3.2–39.6 months) and for progressing patients 3.9 months (0.9–9.2 months).
There was a numeric difference in OS between PS 0/1 and 2/3 patients: median 23 months
(95%CI = 20–26 months) vs 13 months (95%CI = 7–21 months). The difference is statistically
not significant according to log rank test p = 0.687, probably due to the small numbers.
Median overall survival was 25 months (95%CI = 20–29 months) for the younger patients
and 15 months (95%CI = 0–30 months) OS for the elderly patients with a p-value of 0.222.
Despite the numeric difference there is extensive overlap in outcomes.
Fig 2. Survival outcome. Kaplan-Meier curves for overall and progression free survival of the FIELT cohort.
doi:10.1371/journal.pone.0147599.g002
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A similar non-significant ratio was observed with a cut-off of 70 years (used in geriatrics)
with a median OS of 26 months (95%CI = 23–28 months) vs 20 months (95%CI = 10–29
months)
At the time of analysis six patients were alive with median treatment duration on erlotinib
of 18 months (11–32 months) of which three had been switched to gefitinib for tolerance
reasons.
Median treatment duration was 12.8 months (0.6–33 months) and average treatment dura-
tion was 13.3 months. When we also consider the patients that were eligible, but never received
erlotinib the median treatment duration is 10.4 months (0–33 months).
Eight patients (17%) (Table 3) failed within 12 weeks on erlotinib, (median PFS 2.8 months)
of treatment initiation, and they were therefore considered as being de novo resistant to erloti-
nib. These patients had a much shorter OS of 5.6 months (1–26 months) compared to the over-
all 24 months median OS of the other patients (p< 0.002, two-sided). One patient however had
a survival of 26 months despite an erlotinib treatment that lasted only four months, reflecting
the impact of subsequent chemotherapy in this patient population. Factors that could explain a
lack of response are an exon 20 mutation for two patients [18] and a heavy smoking history for
one patient. Other past smokers benefited from erlotinib treatment albeit less than the overall
study population: one 15 pack year: one 8 month PFS; one 5 pack year: one 18 month PFS; one
1 pack year, immediate progression.
Some never smokers with an exon 19 deletion mutation were also de novo resistant
(Table 3).
One patient with an exon 18 mutation that is generally sensitive to EGFR TKI [19], failed
immediately, received one second line of therapy and survived for 9 months.
Post-study treatment
All patients had stopped erlotinib treatment at the time of analysis. Second- and further- lines
of treatment were as reported by the participating centers. Twenty-nine (64%) of the 45
patients for whom the information was available received one or more second or further line
treatments. For sixteen patients (36%) no second-line treatment was reported. For one patient
the information was not available. Seventeen of the 29 (59%; 38% of total) received only one
second-line therapy, nine (31%) received also a third-line and three (10%) also received also a
fourth-line. Of the 29 patients who did receive further therapy, 17 received a targeted agent (7
gefitinib, 9 afatinib, one continued erlotinib beyond progression).
Table 3. Characteristics of patients that failed early on erlotinib.
Initials Sex Age EGFR mutation Smoking status Survival (months)
180 CV F 73 EX 19 (p.Glu746_Ala750del) Never 0.9
173 LAL F 72 EX 20 (p.Asn771del insValHis)* Never 3.2
229 FM F 64 EX 19 (p.Glu746_Ala750del) Never 3.7
241 DEL M 78 EX 21 p.Leu858Arg 25 pack year 3.9
224 FPM F 42 EX 19 p.Leu747_Pro753delins Ser Never 7.4
208 VEC F 48 EX 18 p.Gly719Ala One year 9.2
42 TF F 38 EX 20 p.Ser768_Asp770dup** Never 14
8 MI F 35 EX 21 p.Leu858Arg Never 26.2
* Novel mutation
** reported once in COSMIC database; all other mutations are recurrent.
PY: pack years; F: female; M: male; ex: exon
doi:10.1371/journal.pone.0147599.t003
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Seventeen patients received chemotherapy, of which ten a platinum-based doublet. Seven
patients received only (sequential) single agent chemotherapies. Three of these patients were
more than 75 years old. Four patients received radiotherapy to the brain (three) and the chest
(one).
Safety
Treatment with erlotinib was generally well tolerated with manageable toxicity as reported by
the participating investigators (Table 4). One patient died without disease progression and one
stopped because of skin toxicity while still responding after 18.9 months of treatment and sub-
sequently received gefitinib with a continued sustained response and good tolerance.
Discussion
At the time of initiation of the current phase II study no prospective data were available about
the efficacy of EGFR TKI in EGFR mutant lung cancers. This has changed dramatically since,
as several randomized studies have shown that both gefitinib and erlotinib as reversible EGFR
inhibitors and afatinib as a covalent pan-HER inhibitor outperform chemotherapy as a first-
line therapy in these patients with regard to PFS and QOL [10–13]. Most of the studies have
been performed in Asian or predominantly Asian populations. Only a few studies have been
conducted in homogeneous Caucasian populations, and the current study is the only one to
supplement the data generated with erlotinib in the EURTAC study [12].
The two most representative landmark studies are the iPASS study with gefitinib in an
Asian population [11] and the EURTAC study with erlotinib in a European Caucasian popula-
tion [12]. More recently, similar results were obtained in the LUX-Lung 3 study with the irre-
versible pan-HER inhibitor afatinib [20]. Afatinib resulted in a major improvement in PFS
versus the optimal standard chemotherapy (pemetrexed and cisplatin) for this type of lung
cancer. No survival benefit has generally been observed in these studies, attributed to the
important crossover to TKI as a second-line treatment in the chemotherapy arms, except for
afatinib in patients with a del19 EGFR mutations in the tumor [21].
The PFSR at three months of 81% in the current study exceeds the primary endpoint of the
study that hypothesized a PFSR of> 70%.
The inclusion of 10% of mutations in exon 20 that are less sensitive to EGFR TKI [22]
makes our population less favorable than in the two randomized studies with erlotinib that
included only patients with sensitizing mutations. Despite this, the PFS of 11 months in our
study is intermediate between the PFS of 13 months in the Optimal study [23] and the PFS of
9.7 months in the EURTAC study [12]. In the more recent Lux-Lung 3 study with afatinib that
also included other mutations than exon 19/21, the PFS was 11.1 months, similar to our out-
come [20].
The median OS was 23 months in the current study, 22 months in the Optimal and 19.3
months in the EURTAC study. The current phase II study thus further clarifies the exact
impact of erlotinib in Caucasian patients with an EGFR mutation-positive adenocarcinoma,
indicating that erlotinib has a similar therapeutic impact in Caucasian as in Asian patients.
Table 4. Common toxicities.
Grade 1 Grade 2 Grade 3
Skin rash 14 17 10
Diarrhea 16 14 4
Ocular toxicity 10 11 0
doi:10.1371/journal.pone.0147599.t004
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Treatment beyond progression was limited as median treatment duration was approxi-
mately two months longer than the PFS, similar to the OPTIMAL study. This occurred despite
the protocol specification that patients could be treated until progression and indicates clinical
benefit beyond progression.
Of interest, older patients benefited as much as younger patients. Most of these patients
might otherwise not have benefited from optimal doublet chemotherapy and consequently the
availability of EGFR targeted treatments has a large impact on this population introducing an
effective treatment for a previously unmet medical need. This is in line with other data
obtained with gefitinib [24].
The mutation detection rate was high (24%) in this phenotypically preselected population.
In a more diluted general Caucasian lung cancer population the mutation rate is 10% or less. In
the EURTAC study in a population similar to ours, the mutation rate (only exons 19 and 21)
was 16.6%. Today, in routine practice upfront reflex EGFR mutation testing should be per-
formed in all patients with adenocarcinoma of the lung and in squamous cell lung cancer with
a non-smoking history.
We used a generic method for mutation testing that covered all exons encoding the kinase
domain of EGFR. This method had a high sensitivity of 93% similar to the sensitivity of com-
mercial kits such as Cobas1 and Dxs Therascreen1. In the current cohort five novel muta-
tions were identified, not present in the Cosmic data-base (http://cancer.sanger.ac.uk/
cancergenome/projects/cosmic/). Several unique mutations would possibly not have been
detected by the DxS Therascreen (9/56) and Cobas (8/56) commercial diagnostic mutation
detection kits (Table 1). This includes sensitizing mutations which would have been denied an
EGFR TKI therapy when using these commercial kits.
The small proportion of false negatives (7%) is not overlapping between both approaches:
in the commercial kits some not listed sensitizing mutations can be missed but these methods
can detect highly diluted mutations whereas our method was limited with regard to the dilution
of the mutant DNA, which we proved subsequently by using a more sensitive technique. For
the same reason, our method was unable to identify minority mutations such as the T790M,
which at that time seemed of minor importance for the first-line therapy as it had no impact
on the therapeutic strategy. This has changed with the documentation of a negative prognostic
impact [25] and with the development of novel third generation EGFR inhibitors that can
inhibit the T790M EGFR and their exploration in first-line setting [26].
The few false negatives with either method are unacceptable when one considers the thera-
peutic implications. Therefore, we and others have switched to an amplicon-based deep
sequencing method (Roche 454 technology, Roche Diagnostics Belgium) that allows maximal
detection of mutations and also allows simultaneous examination of other drugable genes with-
out having to resort to sequential diagnostics. It is thereby important that all EGFR kinase
domain exons are included in the analysis.
In the 10% of patients in whom biopsies are quantitatively or qualitatively insufficient,
repeat biopsies in metastatic sites (immediately or later in the disease course) should be done
as soon as feasible and acceptable to the patient. It is important that this specific recommenda-
tion is included in the report to the clinician whenever this might be relevant. An alternative
would be to develop the collection and molecular analysis of circulating tumor cells which, for
lung cancer, is not yet optimally developed. Analyzing plasma DNA (cfDNA) has been vali-
dated as a more efficient and straightforward method for the diagnosis of EGFR mutations in
patients in whom a tissue diagnosis is not possible [27].
The incomplete translation of mutation detection to treatment in a prospective setting is
surprising as 18% eligible patients did not enter the treatment phase with erlotinib. A similar
drop-out rate (16%) has also been observed in the phase II study by Rosell et al [28]. In the
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EURTAC study 10% of patients did not receive erlotinib per protocol after randomization [12].
In the Chinese Optimal study, 99% of those allocated to erlotinib received at least one dose of
study drug [13], a remarkable compliance that might have a cultural basis.
Seventeen percent of the patients failed early and were considered as being de novo resistant
to erlotinib. The median OS for these patients was much shorter, but not necessarily in each
patient. Indeed one patient, treated in second- line with carboplatin-gemcitabine survived for
26 months, illustrating the complementarity of therapeutics for these patients. There are sev-
eral mechanisms of de novo resistance to EGFR TKI [29], but an explanation cannot be found
in all patients.
We were unable to identify characteristics that could predict TKI resistance in most of these
patients. Three patients with an exon 20 mutation did not do well, with two failing early and
one achieving SD but with an OS of only 9 months. But there were also three non-smokers
with an exon 19 mutation that failed early. In one series a KRAS mutation was found to coexist
with EGFR mutation in 2/40 cases [29], but this was not the case in our patients. One of these
patients was a heavy and current smoker who failed immediately. We hypothesize that in
smokers the EGFR mutation occurs in a context in which a large number of cigarette induced
mutations also drive the malignant phenotype and dilute the pathogenic and therapeutic rele-
vance of the mutant EGFR. There is also evidence that in current smokers nicotine diminishes
the effectiveness of EGFR-TKI [30].
Further genomic studies could in the future bring to light mechanisms of de novo and
acquired resistance and prompt the investigation of upfront combined therapeutic strategies.
The proportion of patients receiving a second-line treatment was low (only 33% chemother-
apy and 28% TKI). Only twelve patients received two or more lines of further treatment, one of
which received five lines of further therapy and is still alive at 38+ months. For eighteen
patients (39%) the local investigators reported no second-line systemic treatment. A similar
observation was made in the Optimal study in which 31% of the patients in the erlotinib arm
did not receive a second-line treatment [13].
These data are surprising in view of the relatively high efficacy of chemotherapy in such
patients. It suggests that in practice erlotinib might be continued beyond progression until the
disease rapidly deteriorates, the patient’s condition might become less eligible or the patient is
less willing to be further treated with chemotherapy. The general consensus is that EGFR-TKI
should be given upfront considering their tolerability compared to chemotherapy leading to a
more prolonged preservation of QOL [31]. If the opportunity is missed in the first-line, then
these patients should receive a TKI in any subsequent line, as early as possible. In patients in
whom baseline genotyping was non-conclusive, attempts should be made to repeat biopsies
and genotyping upon progression.
Conclusion
In this prospective phase II study in phenotypically selected patients with a somatic EGFR
mutation in their tumor erlotinib was well tolerated and highly effective in the majority of the
patients. The study further clarifies the impact of first-line erlotinib in EGFR mutant lung can-
cer in Caucasian patients. Elderly patients seem to benefit from EGFR-TKI as well as younger
patients, thus filling an important medical need.
In order to minimize the false negativity rate, the most sensitive method for mutation detec-
tion should be used (deep sequencing of all kinase domain exons) in order not to deny patients
a TKI treatment. Mechanisms underlining primary resistance to EGFR TKI need further
exploration.
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